文献速递神经肿瘤

荷兰成人型高级别弥漫性胶质瘤的新一代测序:初诊与复发情境下实验室间差异

Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
PubMed 文献 · J Neurooncol · 2024-01-29

本研究以荷兰全国性问卷调查(神经病理学家与分子病理临床科学家)了解成人型高级别弥漫性胶质瘤的新一代测序应用现状。12家神经肿瘤中心中11名(神经)病理学家与7名分子病理临床科学家作答,各中心诊断用NGS panel基因数为12至523不等;复发疾病寻找治疗靶点时差异更明显,约半数中心检测基因融合(60%)与肿瘤突变负荷(40%)。作者认为应减少此类实验室间差异以改进诊断与精准肿瘤学。

要点

  • 各中心诊断用NGS panel组成不同,基因数从12至523不等。
  • 复发疾病寻找治疗靶点时,60%的中心检测基因融合、40%检测肿瘤突变负荷。
  • 作者认为应减少实验室间差异以改进诊断与精准肿瘤学。

核心结论

  • 当前存在的实验室间差异应予以减少,以改进诊断并提升精准肿瘤学水平。
  • 自建检测、标准化panel与常规应用广谱基因panel各有优缺点。
  • 未来研究值得探讨诊断方法差异的临床影响。

研究设计与样本

  • 荷兰全国性问卷调查,通过在线问卷收集(神经)病理学家与分子病理临床科学家(CSMPs)在临床与技术方面的做法。
  • 主要结局为各中心用于高级别成人型弥漫性胶质瘤(HGG)诊断实践的panel组成概览,次要结局包括复发HGG的实践与未来展望。
  • 12家神经肿瘤中心中,由11名(神经)病理学家和7名CSMPs填写问卷。

主要发现

  • 各中心诊断用NGS panel组成不同,基因数范围为12至523。
  • 在复发疾病寻找治疗靶点时差异更明显:约半数中心检测基因融合(60%)与肿瘤突变负荷(40%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Next generation sequencing (NGS) is an important tool used in clinical practice to obtain the required molecular information for accurate diagnostics of high-grade adult-type diffuse glioma (HGG). Since individual centers use either in-house produced or standardized panels, interlaboratory variation could play a role in the practice of HGG diagnosis and treatment. This study aimed to investigate the current practice in NGS application for both primary and recurrent HGG. METHODS: This nationwide Dutch survey used the expertise of (neuro)pathologists and clinical scientists in molecular pathology (CSMPs) by sending online questionnaires on clinical and technical aspects. Primary outcome was an overview of panel composition in the different centers for diagnostic practice of HGG. Secondary outcomes included practice for recurrent HGG and future perspectives. RESULTS: Out of twelve neuro-oncology centers, the survey was filled out by eleven (neuro)pathologists and seven CSMPs. The composition of the diagnostic NGS panels differed in each center with numbers of genes ranging from 12 to 523. Differences are more pronounced when tests are performed to find therapeutic targets in the case of recurrent disease: about half of the centers test for gene fusions (60%) and tumor mutational burden (40%). CONCLUSION: Current notable interlaboratory variations as illustrated in this study should be reduced in order to refine diagnostics and improve precision oncology. In-house developed tests, standardized panels and routine application of broad gene panels all have their own advantages and disadvantages. Future research would be of interest to study the clinical impact of variation in diagnostic approaches.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. van Opijnen MP, Broekman MLD, Cuppen E, et al. Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting. J Neurooncol. 2024. PMID: 38285243. doi:10.1007/s11060-024-04568-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。